Why Orexo stock moves
Orexo fell slightly, more than the market.
Written after the close on ·
Why today
16,437 news analyzed todayOrexo fell slightly, more than the market.
OMX Stockholm 30 fell clearly the same day, so Orexo's drop was milder than the index's.
Over the last five trading days Orexo fell very sharply while the market was roughly flat.
That fall was very big for Orexo, rarer than any five-day stretch in the past year.
The main driver is the rights issue, which sets a low subscription price of SEK 0.80 and dilutes existing shares.
Today's move of −1.58% was 0.7 times a normal day's 2.2%. OMX Stockholm 30 moved −1.01% on the same day.
Orexo −1.58%OMX Stockholm 30 −1.01%A little weaker than the market
What analysts expect, and how often they have been right
Analysts’ estimates for Orexo.
Orexo earned more than expected in 3 out of 8 reports.
Not in the chart because no estimate and result are available: 4 of the 12 reports in this period, the latest on October 22, 2026.
For comparison, about 46% of reports from Nordic companies beat the estimate in the last three years.
The share moved in the same direction as the earnings surprise in 6 out of 8 reports with a measured move, against about 63% of reports from Nordic companies.
Price targets
Latest price 1.37 SEK
Earnings against expectations, and the share’s reaction
Expected EPSAbove estimateBelow estimateAs expectedSEK
For the current fiscal year, expected earnings per share changed from -9.03 SEK three months ago to -10.47 SEK now. 2026 estimate: -10.47 SEK. 2027 estimate: -7.28 SEK. One analyst made these estimates.
Has the share price followed the business?
Price and earnings moved in the same direction: 1 out of 3 years. Across Nordic companies, that happens in about 60% of years. In 2025, the price changed +72% and earnings per share went from -13.86 SEK to -11.65 SEK.
Revenue, profit and market cap
RevenueProfitMarket capbn SEK
Assets, liabilities and market cap
AssetsLiabilitiesMarket capbn SEK
Price and earnings moved in the same direction: 1 out of 3 years.Market cap (Now): 48.1 m SEKRevenue 2025: 26.0 m SEK
What the key figures say about Orexo
The figures connect what Orexo earns with what investors pay.
The line shows the share price in the same year, on its own scale. Hatched bars: analysts’ estimates.
Profit divided by the number of shares. Each share represents this much of the earnings.
2022–2025: -13.86 SEK–-3.73 SEK. Peers: Iconovo -0.51 SEK, Cereno Scientific -0.41 SEK, AB Science -0.07 EUR. 2026 estimate: -10.47 SEK (-10.47 SEK–-10.47 SEK). 2027 estimate: -7.28 SEK (-7.28 SEK–-7.28 SEK).
What the company sold during the year.
2022–2025: 26.0 m SEK–639 m SEK. Peers: Iconovo 2.4 m SEK, Cereno Scientific 80.5 m SEK, AB Science 1.2 m EUR.
The percentage of revenue left after the costs of running the business.
2022–2025: −1457.9%–−17.0%. Peers: Iconovo −1528.5%, AB Science 54.4%.
Profit as a percentage of shareholders’ money in the company.
2022–2025: −217.8%–130.3%. Peers: Iconovo −27.3%, Cereno Scientific −61.9%.
What investors pay for each unit the company sells.
2022–2025: 0.83–40.18. Peers: Iconovo 41.72, Cereno Scientific 6.57, AB Science 42.22.
More key figures
Market cap divided by shareholders’ equity, what remains after liabilities.
2022–2025: 2.13–9.04. Peers: Iconovo 0.71, Cereno Scientific 1.92.
Cash left after investments, divided by the number of shares.
2022–2025: -9.60 SEK–-3.31 SEK. Peers: Iconovo -0.43 SEK, Cereno Scientific -0.60 SEK, AB Science -0.05 EUR.
The percentage of assets financed by shareholders’ equity.
2022–2025: −21.2%–37.7%.
What to watch next, and why
The earnings report shows how Orexo's revenue and profit have changed.
- Earnings report
The earnings report shows how Orexo's revenue and profit have changed.
Add to calendar
Earnings report
Next report: · Add to calendar · Google Calendar
On its last 15 report days Orexo usually moved about 4.1%. On a normal day it moves 2.2%.
−3.18% Why? −16.28% −3.11% −7.33%
10,000 SEK in Orexo bought on November 7, 2016 is worth 305 SEK today, with dividends reinvested.
What would 10,000 SEK in Orexo be worth today? →
What would 10,000 SEK in Orexo be worth today?
305 SEK
with dividends reinvested, bought on November 7, 2016.
At worst it was worth 305 SEK (November 6, 2026).
The five biggest days of the journey
· +80.6% · the whole market fell 0.7% the same day
· −64.4% · the whole market fell 0.1% the same day · Why?
· −45.4% · the whole market rose 0.8% the same day
· +30.9% · the whole market rose 0.4% the same day
· +29.6% · the whole market fell 0.2% the same day
Earlier days
−70.86% market −0.11% Orexo fell very sharply over the week, while the wider Stockholm market was roughly flat. Read →
Orexo fell very sharply over the week, while the wider Stockholm market was roughly flat.
The drop was likely driven by the company's rights issue, a share sale that raises new money from existing shareholders at a steep discount, announced on 2 November with a subscription price of 0.80 SEK.
Shareholders approved the issue at an extraordinary general meeting on 6 November, and subscriptions run from 12 to 26 November.
Short selling, betting against the stock, also rose in late October and early November, which may have added pressure.
−4.01% market −0.32% Orexo fell, moving well apart from the market. Read →
Orexo fell, moving well apart from the market.
Shares dropped as the rights issue was priced at SEK 0.80, far below the recent price.
The stock had already fallen sharply over the last five trading days, while the OMX Stockholm 30 rose slightly.
Trading volume was well above normal, and the stock sits at its lowest close of the year.
−3.34% market +0.83% Orexo fell as its rights issue was priced at SEK 0.80. Read →
Orexo fell as its rights issue was priced at SEK 0.80.
Over the same day the Stockholm market rose clearly, so Orexo moved against the market.
A rights issue lets existing shareholders buy new shares at a set price, and a price this far below the market price makes the new shares cheap compared with the current one.
Subscription, the period when shareholders can buy the new shares, runs from 12 to 26 November 2026.
−64.38% market −0.08% Orexo fell as rights issue terms were set. Read →
Orexo fell as rights issue terms were set.
Over the last five trading days, Orexo fell very sharply while the OMX Stockholm 30 rose slightly.
Dilution from new shares and selling pressure from the issue likely drove the decline.
Shares are priced near their lowest close of the year.
−10.44% market +0.48% Orexo fell sharply without company news. Read →
Orexo fell sharply without company news.
Orexo fell very sharply in the last session while OMX Stockholm 30 rose slightly, so the stock moved against the market.
The fall came on heavy trading, roughly twice a normal session, and the move was about five times a typical day for the stock.
Over the last five trading days, Orexo fell very sharply while the market rose clearly, a move about three times a normal five-day stretch.
Peer Healthcare stocks on Nasdaq Stockholm rose modestly over the same days, so the sector did not drive the fall.
−9.88% market +3.01% Orexo fell sharply over the last five trading days, moving against a market that rose clearly. Read →
Orexo fell sharply over the last five trading days, moving against a market that rose clearly.
The move was big for Orexo, rare compared with its usual weekly swings.
The FDA accepted the resubmitted Izipry application on Thursday 29 October and set a decision target of 29 March 2027, which was the week's main company news.
Over the same days the healthcare sector rose modestly, so Orexo's fall was company-specific.
−2.55% market +0.41% Orexo fell clearly. Read →
Orexo fell clearly.
FDA accepted the resubmitted IZIPRY application for review on the trading day, with a decision expected by late March 2027.
The share price also fell over the last five trading days, while the market rose sharply.
The drop is likely partly due to the company's recent weak third-quarter results, a rights issue of about SEK 250 million, and heavy short-selling that has been rising.
Next, watch for the extraordinary general meeting on November 6, 2026, which will vote on the rights issue.
−3.38% market +0.33% Orexo fell, moving against a slightly rising market. Read →
Orexo fell, moving against a slightly rising market.
No company news from that session explains the move.
Over the last five trading days, Orexo fell sharply while the market rose slightly.
The move was big for Orexo, roughly twice a normal five-day stretch.
The Q3 report, published before the session, showed a sharp revenue drop and a wider loss, which likely weighed on sentiment.
−4.50% market +0.96% Orexo fell sharply; no company news explains it. Read →
Orexo fell sharply; no company news explains it.
Orexo fell sharply over the last five trading days, while the Stockholm market was roughly flat.
In the last session it fell sharply while the market rose clearly, so it moved against the market.
No company news from that session explains the move.
Earlier news, including the Q3 report and a rights issue, is background.
−12.29% market −3.67% Orexo fell sharply over the last five trading days, a bigger drop than the wider Stockholm market. Read →
Orexo fell sharply over the last five trading days, a bigger drop than the wider Stockholm market.
The fall came after its third-quarter report, which showed a deeper loss and almost no revenue.
Investors also reacted to the planned rights issue, a share sale that can dilute existing shareholders.
Its shares sit close to their lowest level of the past year.
−3.18% market −2.51% Orexo fell sharply as Q3 results and a rights issue weighed on it. Read →
Orexo fell sharply as Q3 results and a rights issue weighed on it.
Orexo moved in line with the broader Stockholm market in the last session, which fell clearly.
Over the last five trading days, Orexo fell sharply, moving more than OMX Stockholm 30, which also fell clearly.
The move was big for Orexo, rarer than most five-day stretches, and trading volume was heavy.
Likely drivers are the third-quarter report, showing a weak revenue and a larger loss per share, plus the planned SEK 250 million rights issue, which dilutes existing shareholders, and the share price now sits at its lowest close of the past year.
Learn more · Why do stocks go up and down?